RT Journal Article
SR Electronic
T1 Modelling the impact of initiation delay, duration and prior PrEP usage on the prophylactic efficacy of FTC/TDF-containing post-exposure prophylaxis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.22.24310798
DO 10.1101/2024.07.22.24310798
A1 Zhang, Lanxin
A1 Collins, Simon
A1 Fox, Julie
A1 von Kleist, Max
YR 2024
UL http://medrxiv.org/content/early/2024/07/22/2024.07.22.24310798.abstract
AB Introduction Pre- and post-exposure prophylaxis (PrEP and PEP) are important pillars of the HIV prevention portfolio to reduce the risk of infection just before or after HIV exposure. While PrEP efficacy has been elucidated in many randomized clinical trials, corresponding data for PEP is extremely difficult to obtain in a controlled setting. Consequently, it is almost impossible to study the impact of PEP initiation delay and duration on HIV risk reduction clinically, which would inform recommendations on PEP use.Methods We employ pharmacokinetics, pharmacodynamics, and viral dynamics models, along with individual factors, such as drug adherence to investigate the impact of initiation delay and PEP duration on HIV risk reduction. We evaluated PEP using two- and three-drug regimens with a FTC/TDF backbone. Moreover, we study PEP efficacy in the context of PrEP-to-PEP transitions.Results In our simulations, early initiation of PEP emerged as a pivotal factor for HIV risk reduction. We found that 2-drug (FTC/TDF) PEP may insufficiently protect when initiated > 1 hour post- exposure. When adding a third drug, early initiation was still a critical factor, however, over 90% efficacy could be achieved when PEP was initiated 48hours post-exposure and taken for at least 14-28days, depending on the efficacy of the third-drug component. When investigating PrEP- PEP transitions, we observed that preceding PrEP can (i) contribute directly to prophylactic efficacy, and (ii) boost subsequent PEP efficacy by delaying initial viral dynamics and building-up drug concentrations, overall facilitating self-managed transitioning between PrEP and PEP.Conclusions Our study confirms the critical role of early (< 48hours) PEP initiation, preferably with three drugs taken for 28days. Self-start with TDF/FTC and later addition of a third drug is better than not self-starting. Furthermore, our study highlights the synergy between recent PrEP intake and PEP and may help to inform recommendations on PEP use.Competing Interest StatementThe authors have declared no competing interest.Funding StatementM.v.K. acknowledges funding from the German ministry for science and education (BMBF), grant number 01KI2016, from the DFG research center MATH+, as well as Sonderforschungsmittel (SoFo) provided through the Robert-Koch Institute. The funders had no role in the design of the study or the decision to publish.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online at https://github.com/KleistLab/PEP https://github.com/KleistLab/PEP